Mannatech Inc

Análisis de la acción Mannatech Inc (MTEX)

$8.110

+0.050 (+0.62%)Al cierre

Loading chart…
Máximo
8.640
Apertura
8.290
Precio medio ponderado por volumen
8.17
Volumen
10.84K
Capitalización
13.10M
Mínimo
7.770
Importe
88.58K
EV/EBITDA, TTM
0.00

Mannatech, Incorporated is a global health and wellness solution provider. The Company develops and sells nutritional supplements, skin care and anti-aging products, and weight-management products that target optimal health and wellness. The Company's product category includes Integrative Health, Targeted Health, Weight and Fitness, Skin Care, and Essentials. Integrative Health includes Ambrotose Complex, Ambrotose AO, Advanced Ambrotose, Ambrotose Life, Catalyst, Cognitate, Manapol Powder, MannaBears, and others. Targeted Health includes BounceBack, CardioBALANCE, GI-ProBalance Slimstick, GI-Zyme, GI-Defense, Blood Sugar ProBalance, ImmunoSTART, and others. Weight and Fitness includes OsoLean, SPORT, TruHealth Fat Loss System and others. Skin Care includes Emprizone, FIRM with Ambrotose, FreshDen, and others. Essentials include Catalyst Multivitamin, Liver Support, Joint Support SUPERFOOD, Sleep Support gummies and Stress Support gummies.

us.mannatech.com

Análisis de IA of Mannatech Inc (MTEX)

Mantener

Mannatech Inc is not a strong buy right now due to its current price of $8.11, which is significantly below its 52-week high of $9.97. The RSI of 41.05 indicates the stock is nearing oversold territory, but the recent 5-day change of -4.25% suggests downward momentum. The upcoming earnings report on November 11 could provide more clarity on its financial health, but the company has faced declining revenues, with a 6.2% year-over-year decrease reported for Q1 2026.

Métricas de valoración

El PER previsto actual de Mannatech Inc (MTEX) es 9.57, frente a su media de 5 años de 1.70.

PER previsto

Muy sobrevalorado
Media 5A P/E
1.70
P/E actual
9.57
Sobrevalorada
5.22
Infravalorada
-1.83

EV/EBITDA previsto

Muy infravalorado
Media 5A EV/EBITDA
0.00
EV/EBITDA actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Precio/ventas previsto

Muy infravalorado
Media 5A P/S
0.00
P/S actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Escenarios de precio de Alphio AI para MTEX

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%MTEX

$9.48

Precio del escenario

B

Base

Base · 50%MTEX

$7.93

Precio del escenario

B

Bajista

Bajista · 25%MTEX

$7.87

Precio del escenario

Cronología de eventos

2026-09-24 (ET)

10:00:00

Mannatech Trading Halted Due to Volatility

2026-09-01 (ET)

16:30:00

Mannatech Board Chairman Change Announced

2026-08-14 (ET)

14:30:00

Mannatech Trading Resumes

14:30:00

Mannatech Trading Halted Due to Volatility

2026-04-07 (ET)

16:00:00

Mannatech Trading Halted Due to Volatility

Noticias

Preguntas frecuentes sobre MTEX, respondidas por Alphio AI

Mannatech, Incorporated is a global health and wellness solution provider. The Company develops and sells nutritional supplements, skin care and anti-aging products, and weight-management products that target optimal health and wellness. The Company's product category includes Integrative Health, Targeted Health, Weight and Fitness, Skin Care, and Essentials. Integrative Health includes Ambrotose Complex, Ambrotose AO, Advanced Ambrotose, Ambrotose Life, Catalyst, Cognitate, Manapol Powder, MannaBears, and others. Targeted Health includes BounceBack, CardioBALANCE, GI-ProBalance Slimstick, GI-Zyme, GI-Defense, Blood Sugar ProBalance, ImmunoSTART, and others. Weight and Fitness includes OsoLean, SPORT, TruHealth Fat Loss System and others. Skin Care includes Emprizone, FIRM with Ambrotose, FreshDen, and others. Essentials include Catalyst Multivitamin, Liver Support, Joint Support SUPERFOOD, Sleep Support gummies and Stress Support gummies. It operates in the Consumer Non-Cyclicals sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

Mannatech Inc is not a strong buy right now due to its current price of $8.11, which is significantly below its 52-week high of $9.97. The RSI of 41.05 indicates the stock is nearing oversold territory, but the recent 5-day change of -4.25% suggests downward momentum. The upcoming earnings report on November 11 could provide more clarity on its financial health, but the company has faced declining revenues, with a 6.2% year-over-year decrease reported for Q1 2026.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar